AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05127148 — intervention group
Intervention type: OTHER
Intervention: Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
Description: Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
Study NCT05809713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-enabled Team Care
Description: Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
Study NCT05809713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
Study NCT06066996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Blinded Nicotine Patch
Study NCT06066996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nicotine Patch
Description: Blinded Patch with No Nicotine
Study NCT06078774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Health Coach
Description: Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management.
Study NCT05615363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 10mg group
Description: OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
Study NCT05615363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 5mg group
Description: OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
Study NCT05615363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 2mg group
Description: OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
Study NCT05615363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 1mg group
Description: OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
Study NCT05994391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LasoperinTM
Description: Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin
Study NCT05615363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet，once-daily oral administration for 14 days
Study NCT05508035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan
Description: The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
Study NCT05994391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placeo
Description: Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose
Study NCT05508035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
Study NCT05173831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
Study NCT05173831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manualized therapy performed by therapist team
Study NCT05542225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
Study NCT05542225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
Study NCT05542225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
Study NCT05542225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
Study NCT04723888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-ketoglutarate
Description: alpha-ketoglutarate supplements
Study NCT05209776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral immunological assessment on venous blood
Description: Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
Study NCT05469867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat EverPatch
Description: The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
Study NCT05209776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunological assessment carried out on intracardiac material
Description: Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
Study NCT04545983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion Analysis
Description: Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
Study NCT04545983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
Study NCT05738070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
Study NCT05326633 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Description: Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
Study NCT04391218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Approach Group
Description: Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
Study NCT05204771 — intervention group
Intervention type: OTHER
Intervention: Ultrasound exam
Description: Ultrasound exam
Study NCT05204771 — intervention group
Intervention type: OTHER
Intervention: Postnatal abdominal ultrasound
Description: Postnatal abdominal ultrasound
Study NCT05204771 — intervention group
Intervention type: OTHER
Intervention: Pediatric Follow up
Description: Pediatric Follow up
Study NCT05239403 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study NCT05239403 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05202353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906
Study NCT05202353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 456906
Description: BI 456906
Study NCT05202353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide
Study NCT05202353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide
Study NCT05131464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310, 300 mg/2 mL, SC, every 2 weeks
Study NCT06229288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).~Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)
Study NCT06229288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)
Study NCT05476055 — intervention group
Intervention type: GENETIC
Intervention: NGS
Description: In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
Study NCT05032066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Study NCT05032066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Study NCT05826288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioIntelliSense BioButton Rechargable
Description: This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
Study NCT05826288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memora Health two-way patient engagement platform provided by RC
Description: The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
Study NCT04976803 — intervention group
Intervention type: OTHER
Intervention: Determination of ATM alteration status.
Description: ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
Study NCT05239000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric co-management
Description: Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
Study NCT05239000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric guided supportive care
Description: Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
Study NCT05954585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Emergency department treatment as usual
Study NCT05954585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator
Description: Family Navigator will speak with families about individual and systemic issues for linkage to mental health care biweekly for 3 months or until the youth's first mental health appt has been attended, whichever comes first.
Study NCT05804019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and physical interventions
Description: The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
Study NCT05983991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples (blood and bone marrow samples).
Description: For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
Study NCT06093295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)
Description: The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses
Study NCT06093295 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)
Description: The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses
Study NCT05337826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
Study NCT05434845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: An additional 8 mL of blood will be drawn during routine lab collection
Study NCT04897425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful SensoriMotor Therapy Enhanced with Brain Modulation
Description: Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered by intravenous infusion.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel will be administered by intravenous infusion.
Study NCT05818683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered by intravenous infusion.